Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis-Reference-Cited by-同舟云学术

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

Published:2014-02 Issue:2 Volume:146 Page:392-400.e3
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Panaccione Remo,Ghosh Subrata,Middleton Stephen,Márquez Juan R.,Scott Boyd B.,Flint Laurence,van Hoogstraten Hubert J.F.,Chen Annie C.,Zheng Hanzhe,Danese Silvio,Rutgeerts Paul

Funder

Schering-Plough

Merck

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference18 articles.

1. Ulcerative colitis;Danese;N Engl J Med,2011

2. Medical therapy for ulcerative colitis 2004;Hanauer;Gastroenterology,2004

3. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study;Faubion;Gastroenterology,2001

4. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005

5. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee;Kornbluth;Am J Gastroenterol,2010

Cited by 785 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy;Internal Medicine Journal;2024-09-05

2. Strengthening Real‐World Evidence on Question Not Answered by Randomized Trials: A Trial Calibration Approach;Pharmacoepidemiology and Drug Safety;2024-09

3. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial;The Lancet Gastroenterology & Hepatology;2024-09

4. Combined Advanced Targeted Therapy in Inflammatory Bowel Diseases: An Extensive Update;Inflammatory Bowel Diseases;2024-08-29

5. Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study;Digestive and Liver Disease;2024-08